Pharmaceutical Law & Industry Report® Index-Summary

TAMIFLU

– Generic fakes sold on web, 820

TARCERA

– Cancer drug expanded use, FDA panel, 22

TARKA

– Hypertension generic, no injunction (D.N.J.), 775

TASIGNA

– Cancer drug, broader indications, 824
– Leukemia drug website, FDA letter, 1061

TAXATION

– Biomedical applications tax credits, 684
– Excess returns, White House budget proposal, 248
– P.R. tax on foreign firms, 1410

TAXOTERE

– Approval, 1064
– Cancer drug patent invalid for obviousness (D. Del.), 1245

TEFLARO

– Bacterial infection treatment approval, 1411

TEMODAR

– Brain tumor drug, illegal patent extension allegations (D. Del.), 316
– Unenforceability of patent (D. Del.), 119; no marketing during appeal, 385; reversed (Fed. Cir.), 1457

TERRORISM

– Emergency countermeasures, HHS strategy, 1110

TESSALON

– Cough capsules accidental ingestion, 1593

TESTOPEL

– Testosterone promotional materials, 530

TOBI

– Antibiotic false claims settlement, 586

TOPAMAX

– Epilepsy drug off-label use, 584

TRADEMARKS

– Zyprexa counterfeiting conviction vacated (5th Cir.), 320

TRASYLOL

– Bleeding drug product liability, no remand (S.D. Ill.), 12
– Class actions, suits remanded (7th Cir.), 888
– Expert excluded (S.D. Fla.), 1432

TRELSTAR

– Cancer drug formulation approved, 368

TREXIMET

– Migraine drug, generic challenge (E.D. Tex.), 485

TRIBENZOR

– Blood pressure combination approved, 998

TRILEPATL

– Epilepsy drug off-label use, 1269

TROVAN

– Antibiotic clinical trial injuries (U.S., brief filed), 719; (rev den), 852

TYGACIL

– Antibacterial, mortality risk, 1158

TYKERB

– Breast cancer drug approval, 169

TYSABRI

– MS drug, infection risk, 216